Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1997-11-12
2000-09-19
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
4353201, 435 691, 435325, 435 723, 435 911, 435 914, A01N 6300
Patent
active
061207632
ABSTRACT:
The invention provides a method of preventing or reducing the severity of a cancer in a subject by stimulating the subject's immune response against the cancer. The invention provides, for example, a method of stimulating an immune response in a subject by administering to the subject tumor cells that are substantially similar to the subject's cancer cells and that are genetically modified to reduce or inhibit the expression of one or more immunosuppressive agents. The invention also provides a method of preventing or reducing the severity of cancer in a subject by stimulating the subject's immune response against the cancer by administering to the subject tumor cells that are substantially similar to the subject's cancer cells and that are genetically modified to prevent the expression of an immunosuppressive agents and, in combination with the genetically modified tumor cells, an immunostimulatory agent. The invention further provides compositions useful for practicing the claimed methods.
REFERENCES:
patent: 5637483 (1997-06-01), Dranoff et al.
patent: 5681562 (1997-10-01), Sobol et al.
patent: 5731144 (1998-03-01), Toothman et al.
Sulitzeanu, Dov "Immunosupressive Factors in Human Cancer." Adv. Canc. Res. 60:247-267 (1993).
Jachimczak, Piotr et al. "The Effect of Transforming Growth Factor-.beta..sub.2 -Specific Phosphorothioate-Anti-Sense Oligodeoxynucleotides in Reversing Cellular Immunosuppression in Malignant Glioma." J. Neurosurg. 78:944-951 (1993).
Gridley et al., "Effects of Anti-transforming Growth Factor-.beta. Antibody and Interleukin-2 in Tumor-bearing Mice." Canc. Biother. 8:159-170 (1993).
Rosenberg, Steven et al. "Gene Transfer into Humans-Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction." New Engl. J. Med. 323:570-578 (1990).
Lord, E. et al., "Transfection of TGF-.beta. Producing Tumors with IL-2 Elicits Tumor Rejection." Annals of the New York Academy of Sciences. 690:346-348 (1993).
Hirte, H.W. et al., "Reversal of Suppression of Lymphokine-Activated Killer Cells by Transforming Growth Factor-.beta. in Ovarian Carcinoma Ascitic Fluid Requires Interleukin-2 Combined with Anti-CD3 Antibody." Cell. Immun. 142:207-216 (1992).
Hirte, Hal and Clark, David A. "Generation of Lymphokine-Activated Killer Cells in Human Ovarian Carcinoma Ascitic Fluid: Identification of Transforming Growth Factor-.beta. as a Suppressive Factor." Cancer Immun. Immunother. 32:296-302 (1991).
Brabletz, Thomas et al., "Transforming Growth Factor .beta. and Cyclosporin A Inhibit the Inducible Activity of the Interleukin-2 Gene in T Cells through a Noncanonical Octamer-Binding Site." Mole. Cell. Biol. 13:115-1162 (1993).
Ruffini, Pier et al., "Factors, Including Transforming Growth Factor .beta., Released in the Glioblastoma Residual Cavity, Impair Activity of Adherent Lymphokine-Activated Killer Cells." Cancer Immun. 36:409-416 (1993).
Weiskirch, Larry M. et al., "Transforming Growth Factor-.beta.-Mediated Down-Regulation of Antitumor Cytotoxicityof Spleen Cells from MOPC-315 Tumor-Bearing Mice Engaged in Tumor Eradication Following Low-Dose Melphalan Therapy." Cancer Immun. 38:215-224 (1993).
Hanks, Steven K. et al., "Amino Acid Sequence of the BSC-1 Cell Growth Inhibitor (Polyergin) Deduced from the Nucleotide Sequence of the CDNA." Proc. Natl. Acad. Sci. USA. 85:79-82 (1988).
Kuppner, Maria C. et al., "Inhibition of Lymphocyte Function by Glioblastoma-Derived Transforming Growth Factor .beta.2." J. Neurosurg. 71:211-217 (1989).
Bodmer, Stefan et al., "Human Glioblastoma Cell Derived Transforming Growth Factor-.beta.2: Evidence for Secretion of Both High and Low Molecular Weight Biologically Active Forms." J. Neuroimmun. 34:33-42 (1991).
Inge, Thomas H. et al., "Inhibition of Tumor-Specific Cytotoxic T-Lymphocyte Responses by Transforming Growth Factor .beta..sub.1." Cancer Res. 52:1386-1392 (1992).
Yamamoto, Hatsumi et al., "TGF-.beta. Mediates Natural Suppressor Activity of IL-2-Activated Lymphocytes." J. Immunology. 3842-3847 (1994).
International Search Report, International appication No. PCT/US95/09198, date of mailing Nov. 28, 1995.
Tepper, Robert I. and Mule, James J. "Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells." Human Gene Therapy. 5:153-164 (1994).
Wu, S. P. et al., "Repression of Autocrine Transforming Growth Factor .beta..sub.1 and .beta..sub.2 in Quiescent CBS Colon Carcinimoa Cells Leads to Progression of Tumorigenic Properties." Cell Growth & Diff. 4:115-123 (1993).
Gilboa (Seminars in Oncology, vol. 23, 1:101-107, 1996), Jan. 14, 1998.
Arca et al., Cancer Immunol Immonother, 42:237-245, 1996, Jan. 14, 1998.
Mastrangelo et al. (Seminars in Oncology, vol. 23, No. 1, 1996:4-21), Jan. 14, 1998.
Riddell et al. (Nature Medicine, vol. 2, 2:216-223, 1996), Jan. 14, 1998.
Bodmer et al., "Human Glioblastoma Cell Derived Transforming Growth Factor-.beta.2: Evidence for Secretion of Both High and Low Molecular Weight Biologically Active Forms," J. Neuroimmun. 34:33-42 (1991).
Brabletz et al., "Transforming Growth Factor .beta. and Cyclosporin A Inhibit the Inducible Activity of the Interleukin-2 Gene in T Cells Through a Noncanonical Octamer-Binding Site," Mol. Cell. Biol. 13:115-162 (1993).
Gridley et al., "Effects of Anti-Transforming Growth Factor .beta. Antibody and Interleukin-2 in Tumor-bearing Mice," Cancer Biother. 8:159-170 (1993).
Hanks et al., "Amino Acids Sequence of the BSC-1 Cell Growth Inhibitor (Polyergin) Deduced from the Nucleotide Sequence of the cDNA," Proc. Natl. Acad. Sci. USA. 85:79-82 (1988).
Hirte et al., "Reversal of Suppression of Lymphokine-Activated Killer Cells by Transforming Growth Factor-.beta. in Ovarian Carcinoma Ascitic Fluid Requires Interleukin-2 Combined with Anti-CD3 Antibody," Cell. Immunol. 142:207-216 (1992).
Hirte and Clarke, "Generation of Lymphokine-Activated Killer Cells in Human Ovarian Carcinoma Ascitic Fluid: Identification of Transforming Growth Factor-.beta. as a Suppressive Factor," Cancer Immunol. Immunother. 32:296-302 (1991).
Inge et al., "Inhibition of Tumor-Specific Cytotoxic T-Lymphocyte Responses by Transforming Growth Factor .beta..sub.1," Cancer Res. 52:1386-1392 (1992).
Jachimczak et al., "The Effect of Transforming Growth Factor-.beta.-Specific Phosphorothioate-Anti Sense Oligodeoxynucleotides in Reversing Cellular Immunosuppression in Malignant Glioma," J. Neurosurg. 78:944-951 (1993).
Kuppner et al., "Inhibition of Lymphocyte Function by Glioblastoma-Derived Transforming Growth Factor .beta.2," J. Neurosurg. 71:211-217 (1989).
Lord et al., "Transfection of TGF-.beta. Producing Tumors with IL-2 Elicits Tumor Rejection," Annals of the New York Academy of Sciences 690:346-348 (1993).
Rosenberg et al., "Gene Transfer into Human-Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Trasduction," New Engl. J. Med. 323:570-578 (1990).
Ruffini et al., "Factors, Including Transforming Growth Factor .beta., Released in the Glioblastoma Residual Cavity, Impair Activity of Adherent Lymphokine-Activated Killer Cells," Cancer Immunol. 36:409-416 (1993).
Sulitzeanu, Dov, "Immunosupressive Factors in Human Cancer," Adv. Cancer Res. 60:247-267 (1993).
Tepper and Mule, "Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells," Human Gene Therapy 5:153-164 (1994).
Weiskirch et al., "Transforming Growth Factor-.beta.-Mediated Down-Regulation of Antitumor Cytotoxicity of Spleen Cells form MOPC-315 Tumor-Rearing Mice Engaged in Tumor Eradication Following Low-Dose Melphalan Therapy," Cancer Immun. 38:215-224 (1994).
Wu et al., "Repression of Autocrine Transforming Growth Factor .beta..sub.1 and .beta..sub.2 in Quiescent CBS Colon Carcinoma Cells Leads to Progression of Tumorigenic Properties," J. Cell Biology 116: 187-196 (1992).
Yamamoto et al., "TGF-.beta. Mediates Natural Suppressor Activity of IL-2-Activated Lymphocytes," J. Immunol. 3842-3847 (1994).
Dorigo Oliver
Fakhrai Habib
Sobol Robert E.
Campell Bruce R.
Nguyen Dave Trong
Sidney Kimmel Cancer Center
LandOfFree
Compositions and methods for enhanced tumor cell immunity in viv does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhanced tumor cell immunity in viv, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhanced tumor cell immunity in viv will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1069393